dMMR PDAC are enriched for several markers of immune activation (including high tumor mutational burden and neoantigen load, chemokine signatures, and cytolytic activity), are less likely to have mutations in usual PDAC driver genes like KRAS and SMAD4, but more likely to have mutations in genes that drive cancers with microsatellite instability like ACV2RA and JAK1 [83]. This evidence concerns the gene KRAS and neoplasm.